[Prognostic significance of Ph-positive acute lymphoblastic leukemia].

Li Zhou, Jiong Hu, Juan Chen, Shenghong Du, Aihua Wang, Jianhua You, Wen Wu, Zhixiang Shen, Junmin LiPubMed 2014 · DOI

Abstract

allo-HSCT was an optimal choice for Ph⁺ALL patients. Imatinib-based therapy could increase CR rate, maintain CR duration and decrease relapse, resulting in more chance of HSCT. Imatinib improved the outcomes of Ph⁺ALL patients who were not eligible for HSCT.
BibTeX
@inproceedings{zhou2014prognostic,
  author = {Li Zhou and Jiong Hu and Juan Chen and Shenghong Du and Aihua Wang and Jianhua You and Wen Wu and Zhixiang Shen and Junmin Li},
  title = {{[Prognostic significance of Ph-positive acute lymphoblastic leukemia].}},
  booktitle = {PubMed},
  year = {2014},
  doi = {10.3760/cma.j.issn.0253-2727.2014.02.011},
}

Loading related content...

Figure